ARWR (Arrowhead Pharmaceuticals) Buyback Yield % : 0.00 (As of Dec. 11, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Arrowhead Pharmaceuticals Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Arrowhead Pharmaceuticals's current buyback yield was 0.00%.

Arrowhead Pharmaceuticals Buyback Yield % Historical Data

The historical data trend for Arrowhead Pharmaceuticals's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arrowhead Pharmaceuticals Buyback Yield % Chart

Arrowhead Pharmaceuticals Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Buyback Yield %

Get a 7-Day Free Trial

-5.68

-17.82

Arrowhead Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Arrowhead Pharmaceuticals's Buyback Yield %

For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arrowhead Pharmaceuticals's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Arrowhead Pharmaceuticals's Buyback Yield % falls into.

Arrowhead Pharmaceuticals Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Arrowhead Pharmaceuticals's Buyback Yield for the fiscal year that ended in Sep. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	429.265)	/	2409.16312
	=	-17.82%

Arrowhead Pharmaceuticals's annualized Buyback Yield for the quarter that ended in Sep. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(Annualized)			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	*	Annualized Factor	/	Market Cap
	=	- (0	+	0)	*	4	/	2409.16312
	=	0.00%

In calculating the annualized quarterly data, the Repurchase of Stock and Issuance of Stock data used here is four times the quarterly (Sep. 2024) data.

Arrowhead Pharmaceuticals Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Arrowhead Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arrowhead Pharmaceuticals Inc (NAS:ARWR) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

ARWR:Mexico 0HI3:UK HDP1:Germany HDP1:Germany

Address

177 E. Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105

Website

https://www.arrowheadpharma.com

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Executives

Tracie Oliver	officer: Chief Commercial Officer	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Victoria Vakiener	director	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
James C Hamilton	other: Senior Vice President	177 EAST COLORADO BLVD, SUITE 700, PASADENA CA 91105
Kenneth Allen Myszkowski	officer: CFO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Christopher Richard Anzalone	director, officer: President and CEO	ARROWHEAD RESEARCH CORPORATION, 201 SOUTH LAKE AVENUE, SUITE 703, PASADENA CA 91101
Mauro Ferrari	director	201 SOUTH LAKE AVENUE, PASADENA CA 91101
William D. Waddill	director	C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Douglas B Given	director	C/O NEORX CORP, 410 WEST HARRISON ST, SEATTLE WA 98119
Patrick O'brien	officer: General Counsel	225 S. LAKE AVENUE SUITE 1050, PASADENA CA 91101
Martin Javier San	officer: Chief Medical Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
Backer Marianne De	director	177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Michael S Perry	director	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
James Hassard	officer: Chief Commercial Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Curt Bradshaw	officer: Chief Scientific Officer	177 E COLORADO BLVD, STE 700, PASADENA CA 91105